Related references
Note: Only part of the references are listed.A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE
Wenjia Zhu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Intraindividual comparison of18F-FDOPA and68Ga-DOTATOC PET/CTdetection ratefor metastatic assessment in patients with ileal neuroendocrine tumours
Eric Ouvrard et al.
CLINICAL ENDOCRINOLOGY (2021)
18F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study
Tina Binderup et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors
Silvia Nicolini et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
Wenjia Zhu et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy
Jingjing Zhang et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
[18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients
Elin Pauwels et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Preclinical evaluation of a dual sstr2 and integrin αvβ3-targeted heterodimer [68Ga]-NOTA-3PEG4-TATE-RGD
Bingnan Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study
Guillaume P. Nicolas et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms
Richard P. Baum et al.
Oncotarget (2018)
Comparison of the Impact of Ga-68-DOTATATE and F-18-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors
Emmanouil Panagiotidis et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
David L. H. Chan et al.
THERANOSTICS (2017)
68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer
Kun Zheng et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature
Camilla Bardram Johnbeck et al.
FUTURE ONCOLOGY (2014)
68Ga-PRGD2 PET/CT in the Evaluation of Glioma: A Prospective Study
Deling Li et al.
MOLECULAR PHARMACEUTICS (2014)
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours
Stefano Severi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Integrin αvβ3-Targeted Radiotracer 99mTc-3P-RGD2 Useful for Noninvasive Monitoring of Breast Tumor Response to Antiangiogenic Linifanib Therapy but not Anti-Integrin αvβ3 RGD2 Therapy
Shundong Ji et al.
THERANOSTICS (2013)
Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours
Levent Kabasakal et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
Thorsten D. Poeppel et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours
V. Zamora et al.
DIGESTIVE AND LIVER DISEASE (2010)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs
Dik J. Kwekkeboom et al.
NEUROENDOCRINOLOGY (2009)
68Ga-labeled multimeric RGD peptides for microPET imaging of integrin αvβ3 expression
Zi-Bo Li et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2):: synthesis and microPET imaging of αvβ3 integrin expression
Zhanhong Wu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors:: Comparison with somatostatin receptor scintigraphy and CT
Michael Gabriel et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Share Paper
